Online Shop
Abacavir
Aceclofenac
Acyclovir
Adefovir
Alfuzosin
Amiloride
Amlodipine
Amoxycillin
Anastrozole
Atropine
Azathioprine
Azithromycin
Baclofen
Bencyclane
Bicalutamide
Bisacodyl
Bisoprolol
Bosentas
Brimonidine
Butenafine
Calcitriol
Capecitabine
Cefixime
Cefoperazone
Cefotetan
Clindamycin
Clobetasone
Clonidine
Cyclosporine
Cyclosporine
Dacarbazine
Desonide
Dextroamphetamine
Didanosine
Duloxetine
Dutasteride
Efavirenz
Emtricitabine
Estradiol
Etoricoxib
Felodipine
Fenofibrate
Finasteride
Flucloxacillin
Fluvoxamine
Formoterol
Formoterol-Budesonide
Gliclazide
Goserelin
Hepatitis
Hyaluronate
Hydrocortisone
Hydroxyurea
Hypromellose
Indinavir
Insulin
Irinotecan
Isotretinoin
Itopride
Ketoconazole
Lamivudine
Levosalbutamol
Linezolid
Lisinopril
Lopinavir
Mercaptopurine
Mesalazine
Mometasone
Mycophenolate
Nateglinide
Nebivolol
Nelfinavir
Nevirapine
Nitrendipine
Olmesartan
Ondansetron
Ormeloxifene
Ornidazole
Orphenadrine
Oseltamivir
Oxcarbazepine
Oxybutynin
Oxytetracycline
Paracetamol
Paracetamol
Piroxicam
Progestin
Propranolol
Pyrantel
Quetiapine
Rabeprazole
Ranolazine
Risedronate
Rizatriptan
Rosiglitazone
Salbutamol
Saquinavir
Sildenafil
Sorbitol
Sucralfate
Tamsulosin
Telmisartan
Tenofovir
Tobramycin
Torsemide
Venlafaxine
Voriconazole
Warfarin
Zolmitriptan

Fenofibrate.

Structure

Fenofibrate tablets:
- 145 mg - Fenofibrate BP;

Without a Prescription

Treatment of Hypercholesterolaemia.
Fenofibrate is prescribed as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, TG and Apo B and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate.

Dosage

Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of Fenofibrate 145 if lipid levels fall significantly below the targeted range.

Treatment with Fenofibrate should be initiated at a dose of 48 mg/day in patients having mild to moderately impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose.

For adult patients with hypertriglyceridemia, the initial dose is 48 to 145 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 145 mg per day.

For the treatment of adult patients with primary hypercholesterolemia or mixed hyperlipidemia, the initial dose of Fenofibrate 145 is one tablet once daily.

Patients should be placed on an appropriate lipid-lowering diet before receiving Fenofibrate 145 , and should continue this diet during treatment with Fenofibrate 145 . Fenofibrate 145 tablets can be given without regard to meals.

Contraindications


- Hepatic or severe renal dysfunction, including primary biliary cirrhosis and patients with unexplained persistent liver function abnormality;
- Hypersensitivity to Fenofibrate;
- Pre-existing gallbladder disease;

Form

Blister of 10 tablets;

Prescription drugs without a script
Prescription drugs no script
Prescription drugs no prescription
Prescription drugs without a prescription
RX no RX
RX without RX
2004 - 2017